Global Therapeutic Proteins and Oral Vaccines Market Research Report 2023

Therapeutic proteins are engineered in the laboratory for pharmaceutical use. They include non-covalent binders, enzymes and albumin and therefore have a wide range of treatment applications. Oral vaccines are biologically prepared products, which provide active acquired immunity to diseases. There are currently oral vaccines targeting cholera, polio, rotavirus, smallpox and yellow fever, among others. Oral vaccines comprise an agent resembling the disease-causing microorganism, such as a live attenuated or killed viral particle or the micro-organisms toxins or surface proteins.

According to Researcher's new survey, global Therapeutic Proteins and Oral Vaccines market is projected to reach US$ 634.7 million in 2029, increasing from US$ 426 million in 2022, with the CAGR of 5.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Therapeutic Proteins and Oral Vaccines market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Therapeutic Proteins and Oral Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.


By Company


Abbott

Amgen

Biogen

Eli Lilly and Company

Roche

Johnson and Johnson

Merck

Novo Nordisk

Pfizer

Sanofi

Serum Institute of India

Emergent Biosolutions

TransAlgae

MigVax

Lumen Bioscience


Segment by Type


Therapeutic Proteins

Oral Vaccines


Segment by Application


Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The Therapeutic Proteins and Oral Vaccines report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies’ Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies’ Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Frequently Asked Questions